LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, has entered into a business relationship with Kaneka, a global leader ...

NICE has assessed Spectra Optia to help the NHS decide whether to use this product. Spectra Optia is an apheresis and cell collection platform which can be used to treat sickle cell disease. It should ...

In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...

Sepsis is one of the most frequent causes of death worldwide, claiming nearly 11 million lives, accounting for 20% of all global deaths [1, 2] and taking more lives than cancer [3]. This is more than ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...